DNM1L and neoplasm: Although final Drp1(-/17) tumor weights at the endpoint were lower than GFP controls in the cisplatin-treated groups, Drp1(-/17) tumors were multi-lobular and were the only group to develop lymph node lesions with cisplatin treatment (Appendix Fig. S6).